The withdrawal of the cholesterol-lowering drug, Lipobay, by pharmaceutical company Bayer, has prompted an EU safety review of other drugs in the same class.
The European Medicines Evaluation Agency has announced that it will be studying the 'whole class' of these products, in order to determine whether other drugs pose a similar risk.
The review will focus on the class of drugs known as statins, which are similar in make-up to Lipobay. They act by blocking the production of cholesterol.
Statins are commonly prescribed drugs, with total annual sales now worth billions of pounds a year.
